A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522309-40-00

Acronym

TAK-279-VT-2001

Enrollment

144

Registered

2025-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-segmental vitiligo

Brief summary

Proportion of participants achieving ≥75% improvement from baseline in F-VASI at Week 24.

Detailed description

Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24

Interventions

DRUGZASOCITINIB

DRUGWhite opaque

DRUGhard hypromellose capsule

DRUGsize 3 containing same excipients as TAK-279 active capsule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving ≥75% improvement from baseline in F-VASI at Week 24.	—

Secondary

Measure	Time frame
Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24	—

Countries

France, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026